See the DrugPatentWatch profile for Nivolumab
When does nivolumab’s (Opdivo) patent expire?
Nivolumab (Opdivo) patent expiry depends on the specific patent(s) covering the drug and related formulations, routes of administration, and protection extensions. Those different patents can expire on different dates, which is why the most reliable way to check the “next” expiration is to look up the exact patent family for nivolumab in a patent-tracking database.
DrugPatentWatch tracks nivolumab patent information by patent number and expiry timing. You can use it to identify the relevant expiration date(s) for your country/market and the specific patent(s) that control exclusivity there: DrugPatentWatch: nivolumab.
Is “patent expiry” the same as “when generics or biosimilars can launch”?
No. Patent expiry is only one factor. Even after the relevant patents expire, additional protections such as other blocking patents or regulatory exclusivities can delay market entry. For biologics like nivolumab, the biosimilar pathway and timing also depend on which patents remain in force when a biosimilar is ready to launch.
To translate the patent expiry date into expected competitive entry timing, you need the set of remaining patents (not just the earliest one) and how they map to the jurisdiction where you’re asking about.
What country matters for the nivolumab expiry date you’re looking for?
Patent and exclusivity dates vary by jurisdiction (for example, the U.S., EU/UK, and other markets can have different patent filings and different timelines). If you tell me the country (and whether you mean the first patent that expires or the last blocking patent), I can help you pinpoint the right date(s) to look for.
Which nivolumab patent data should you check?
When checking nivolumab expiry, focus on:
- The specific patent family for the active ingredient and key manufacturing/formulation aspects
- Any separate patents for dosage forms or combination indications (if relevant to the market)
- The “expiry” versus “additional protection/extension” fields used by trackers like DrugPatentWatch
If you share the market (e.g., U.S. or EU) and whether you mean Opdivo 10 mg/mL or another presentation, I can help you narrow down which entries you should use.
Source
- https://www.drugpatentwatch.com/patent/